- Home
- PPBT vs MITQ Comparison
PPBT vs MITQ Comparison
Compare PPBT & MITQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBT
- MITQ
- Stock Information
- Founded
- PPBT 2010
- MITQ N/A
- Country
- PPBT Israel
- MITQ United States
- Employees
- PPBT N/A
- MITQ N/A
- Industry
- PPBT Biotechnology: Pharmaceutical Preparations
- MITQ Telecommunications Equipment
- Sector
- PPBT Health Care
- MITQ Telecommunications
- Exchange
- PPBT Nasdaq
- MITQ Nasdaq
- Market Cap
- PPBT 6.2M
- MITQ 5.5M
- IPO Year
- PPBT N/A
- MITQ 2021
- Fundamental
- Price
- PPBT $2.40
- MITQ $0.72
- Analyst Decision
- PPBT Strong Buy
- MITQ
- Analyst Count
- PPBT 1
- MITQ 0
- Target Price
- PPBT $33.00
- MITQ N/A
- AVG Volume (30 Days)
- PPBT 20.0K
- MITQ 9.8M
- Earning Date
- PPBT 08-15-2025
- MITQ 05-15-2025
- Dividend Yield
- PPBT N/A
- MITQ N/A
- EPS Growth
- PPBT N/A
- MITQ N/A
- EPS
- PPBT N/A
- MITQ N/A
- Revenue
- PPBT N/A
- MITQ $18,613,000.00
- Revenue This Year
- PPBT N/A
- MITQ N/A
- Revenue Next Year
- PPBT N/A
- MITQ N/A
- P/E Ratio
- PPBT N/A
- MITQ N/A
- Revenue Growth
- PPBT N/A
- MITQ N/A
- 52 Week Low
- PPBT $2.00
- MITQ $0.50
- 52 Week High
- PPBT $13.95
- MITQ $1.55
- Technical
- Relative Strength Index (RSI)
- PPBT 47.27
- MITQ 61.52
- Support Level
- PPBT $2.35
- MITQ $0.63
- Resistance Level
- PPBT $2.58
- MITQ $0.75
- Average True Range (ATR)
- PPBT 0.12
- MITQ 0.06
- MACD
- PPBT 0.01
- MITQ 0.01
- Stochastic Oscillator
- PPBT 43.75
- MITQ 74.86
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
About MITQ Moving iMage Technologies Inc.
Moving iMage Technologies Inc is engaged in providing designed equipment as well as other off the shelf cinema products needed for contemporary cinema requirements. It offers technical, design and consulting services such as custom engineering, systems design, integration and installation and digital technology, as well as software solutions for operations enhancement and theatre management.